Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics has received positive feedback from the US FDA regarding its planned Phase 2b/3 trial for narmafotinib, a FAK inhibitor, in combination with gemcitabine and Abraxane for pancreatic cancer. The FDA’s support for the dose comparison design and minimal impact on timelines enhances Amplia’s confidence in proceeding with the trial, which is set to begin in late 2026, potentially strengthening its position in the oncology market.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, and FAK also plays a role in chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 1,535,791
Technical Sentiment Signal: Sell
Current Market Cap: A$59M
Learn more about ATX stock on TipRanks’ Stock Analysis page.